Combining statins with tissue plasminogen activator treatment after experimental and human stroke: A safety study on hemorrhagic transformation

CNS Neuroscience and Therapeutics

Volumn 19, Issue 11, 2013, Pages 863-870

  Campos, Mireia ^a   García Bonilla, Lidia ^a   Hernández Guillamon, Mar ^a   Barceló, Verónica ^a   Morancho, Anna ^a   Quintana, Manolo ^b   Rubiera, Marta ^b   Rosell, Anna ^a   Montaner, Joan ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Cerebral ischemia; Hemorrhagic transformation; Spontaneous hypertensive rats; Statins; Tissue plasminogen activator

Indexed keywords

GELATINASE A; GELATINASE B; SIMVASTATIN; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; BRAIN LEVEL; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG SAFETY; ENZYME BLOOD LEVEL; EXPERIMENTAL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MORTALITY; NONHUMAN; RAT; STROKE PATIENT;

CEREBRAL ISCHEMIA; HEMORRHAGIC TRANSFORMATION; SPONTANEOUS HYPERTENSIVE RATS; STATINS; TISSUE PLASMINOGEN ACTIVATOR;

AGED; AGED, 80 AND OVER; ANIMALS; CEREBRAL HEMORRHAGE; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RANDOM ALLOCATION; RATS; RATS, INBRED SHR; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84885943580     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12181     Document Type: Article

References (44)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2102;125:e2-e220.
2. NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
3. NINDS rt-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-pa therapy for ischemic stroke. Stroke 1997;28:2109-2118.
4. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-1329.
5. Chen J, Zhang C, Jiang H, et al. Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice. J Cereb Blood Flow Metab 2005;25:281-290.
6. Hayashi T, Hamakawa K, Nagotani S, et al. HMG CoA reductase inhibitors reduce ischemic brain injury of Wistar rats through decreasing oxidative stress on neurons. Brain Res 2005;10:1037.
7. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-1135.
8. Balduini W, De Angelis V, Mazzoni E, Cimino M. Simvastatin protects against long-lasting behavioral and morphological consequences of neonatal hypoxic/ischemic brain injury. Stroke 2001;32:2185-2191.
9. Rosenson RS. Non -lipid lowering effects of statins on atherosclerosis. Curr Cardiol Rep 1999;1:225-232.
10. Jain MK, Ridker PM. Anti-Inflammatory effects of Statins: Clinical Evidence and Basic Mechanisms. Nat Rev Drug Discovery 2005;4:977-987.
11. Kilic E, Kilic U, Matter CM, Luscher TF, Bassetti CL, Hermann DM. Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor but does not depend on endothelial no synthase. Stroke 2005;36:332-336.
12. Zhang L, Zhang ZG, Ding GL, et al. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation 2005;112:3486-3494.
13. Jonsson N, Asplund K. Does pre-treatment with statins improve clinical outcome after stroke? A pilot-case-referent study Stroke 2001;32:1112-1115.
14. Martí-Fàbregas J, Gomis M, Arboix A, et al. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 2004;35:1117-1121.
15. Montaner J, Chacón P, Krupinski J, et al. Simvastatin in the acute phase of ischemic stroke: A safety and efficacy pilot trial. Eur J Neurol 2008;15:82-90.
16. Salat D, Ribosa R, Garcia-Bonilla L, Montaner J. Statin use before and after acute ischemic stroke onset improves neurological outcome. Expert Rev Cardiovasc Ther 2009;7:1219-1230.
17. Zhang L, Chopp M, Jia L, Cui Y, Lu M, Zhang ZG. Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats. J Cereb Blood Flow Metab 2009;29:1816-1824.
18. Lapchak PA, Han MK. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbits. Brain Res 2009;1303:144-150.
19. Meier N, Nedeltchev K, Brekenfeld C, et al. Prior statin use, intracranial hemorrhage, and outcome after intra-arterial thrombolysis for acute ischemic stroke. Stroke 2009;40:1729-1737.
20. Zhang RL, Chopp M, Zhang ZG, Jiang Q, Ewing JR. A rat model of focal embolic cerebral ischemia. Brain Res 1997;766:83-92.
21. Hernandez-Guillamon M, Garcia-Bonilla L, Solé M, et al. Plasma VAP-1/SSAO activity predicts intracranial hemorrhages and adverse neurological outcome after tissue plasminogen activator treatment in stroke. Stroke 2010;41:1528-1535.
22. Edlow JA, Smith EE, Stead LG, et al. Clinical policy: Use of intravenous tPA for the management of acute ischemic stroke in the emergency department. Ann Emerg Med 2013;61:225-243.
23. Pérez-Asensio FJ, Hurtado O, Burguete MC, et al. Inhibition of iNOS activity by 1400W decreases glutamate release and ameliorate stroke outcome after experimental ischemia. Neurobiol Dis 2005;18:375-384.
24. Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis RL, Bartkowski HM. Evaluation of 2, 3, 5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 1986;17:1304-1308.
25. García-Bonilla L, Sosti V, Campos M, et al. Effects of acute post-treatment with dipyridamole in a rat model of focal cerebral ischemia. Brain Res 2011;1373:211-220.
26. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial TOAST Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
27. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-1025.
28. Waters DD, Schwartz GG, Olsson AG, et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: A myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) substudy. Circulation 2002;106:1690-1695.
29. Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelialnitric oxide synthase in mice. Stroke 2001;32:980-986.
30. Laufs U, Gertz K, Huang P. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 2000;31:2442-2449.
31. Miedema I, Uyttenboogaart M, Koopman K, De Keyser J, Luijckx GJ. Statin use and functional outcome after tissue plasminogen activator treatment in acute ischaemic stroke. Cerebrovasc Dis 2010;29:263-267.
32. Engelter ST, Soinne L, Ringleb P, et al. IV thrombolysis and statins. Neurology 2011;77:888-895.
33. McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: A meta-analysis of 31 randomized controlled trials. Stroke 2012;43:2149-2156.
34. Yamakawa H, Jezova M, Ando H, Saavedra JM. Normalization of endothelial and inducible nitric oxide synthase expression in brain microvessels of spontaneously hypertensive rats by angiotensin II AT1 receptor inhibition. J Cereb Blood Flow Metab 2003;23:371-380.
35. Barone FC, Price WJ, White RF, Willette RN, Feuerstain GZ. Genetic hypertension and increased susceptibility to cerebral ischemia. Neurosci Biobehav Rev 1992;16:219-233.
36. Park KP, Rosell A, Foerch C, et al. Plasma and brain matrix metalloproteinase-9 after acute focal cerebral ischemia in rats. Stroke 2009;40:2836-2842.
37. Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 2002;33:831-836.
38. Batra A, Latour LL, Ruetzler CA, et al. Increased plasma and tissue MMP levels are associated with BCSFB and BBB disruption evident on post-contrast FLAIR after experimental stroke. J Cereb Blood Flow Metab 2010;30:1188-1199.
39. Shabanzadeh AP, Shuaib A, Wang CX. Simvastatin reduced ischemic brain injury and perfusion deficits in an embolic model of stroke. Brain Res 2005;1042:1-5.
40. Nagaraja T, Knight R, Croxen R, Konda K, Fenstermacher J. Acute neurovascular unit protection by simvastatin in transient cerebral ischemia. Neurol Res 2006;28:826-830.
41. Sena ES, Briscoe CL, Howells DW, Donnan GA, Sandercock PA, Macleod MR. Factors affecting the apparent efficacy and safety of tissue plasminogen activator in thrombotic occlusion models of stroke: Systematic review and meta-analysis. J Cereb Blood Flow Metab 2010;30:1905-1913.
42. Koller A, Huang A. Impaired nitric oxide-mediated flow-induced dilation in arterioles of spontaneously hypertensive rats. Circ Res 1994;74:416-421.
43. Alvarez-Sabín J, Huertas R, Quintana M, et al. Prior statin use may be associated with improved stroke outcome after tissue plasminogen activator. Stroke 2007;38:1076-1078.
44. García-Bonilla L, Campos M, Giralt D, et al. Evidence for the efficacy of statins in animal stroke models: A meta-analysis. J Neurochem 2012;122:233-243.